Income StatementBalance SheetCash FlowSegments
Eli Lilly logo

Eli Lilly Cash Flow Statement

Operating, investing, and financing cash movements

Eli Lilly generated $20.5B in operating cash flow over the trailing twelve months. After $8.7B in capital expenditures, free cash flow was $11.8B. Free cash flow increased 2.2% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$20.5BNet Cash From Investing (TTM)-$11.5BNet Cash From Financing (TTM)-$7.1BCapital Expenditures (TTM)$8.7BDepreciation And Amortization Cf (TTM)$2.0BNet Change In Cash (TTM)$988.6M
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$897.72B
P/E Ratio35.52
ROE107.65%

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Acquired in-process research and development—$1.6B$153.8M$655.7M—$584.0M
Acquisitions, net of cash acquired$300.0K$0.0$0.0$549.4M$111.6M$1.1B
Capital expenditures$1.5B$1.5B$1.7B$2.1B$2.5B$2.3B
Other Payments to Acquire Businesses$300.0K$0.0$0.0$549.4M$111.6M$1.1B
Payment for (Proceeds from) Other Investing Activity$678.2M-$111.0M$135.8M$31.0M-$56.8M$31.0M
Payments to Acquire in Process Research and Development$251.4M$1.8B$106.8M$720.5M$423.7M$204.0M
Payments to Acquire Other Investments$151.9M$197.0M$170.9M$150.1M$127.0M$297.0M
Payments to Acquire Other Property, Plant, and Equipment$1.5B$1.5B$1.7B$2.1B$2.5B$2.3B
Net cash from investing activities-$1.9B-$3.4B-$1.8B-$3.0B-$2.8B-$3.9B
Other investing activities$678.2M-$111.0M$135.8M$31.0M-$56.8M$31.0M
Purchases of investments$151.9M$197.0M$170.9M$150.1M$127.0M$297.0M

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Change in accounts payable$652.3M$2.5B$2.5B$2.5B$2.5B—
Change in inventories$626.8M$1.2B$1.2B$1.2B$1.2B—
Change in other assets$832.8M$1.7B$1.7B$1.7B$1.7B—
Other working capital changes$662.3M$474.0M—$302.3M—-$175.0M
Change in receivables$538.8M$1.8B$1.8B$1.8B$1.8B—
Deferred income taxes$966.6M$392.0M$1.1B—$748.1M$1.5B
Depreciation and amortization$485.2M$463.0M$478.3M$470.0M$585.7M$509.0M
Net cash from operating activities$2.5B$1.7B$3.1B$8.8B$3.2B$5.3B
Net income$4.4B$2.8B$5.7B$5.6B$6.6B$7.4B
Increase (Decrease) in Accounts and Other Receivables$538.8M$1.8B$1.8B$1.8B$1.8B—
Increase (Decrease) in Deferred Income Taxes$966.6M$392.0M$1.1B—$748.1M$1.5B
Increase (Decrease) in Prepaid Expense and Other Assets$832.8M$1.7B$1.7B$1.7B$1.7B—
Stock-based compensation$142.3M$154.0M$184.8M$151.1M$136.1M$161.0M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Proceeds from issuance of debt—$6.5B—$6.7B—$0.0
Repayments of debt$166.0M$0.0$778.1M——$750.0M
Dividends paid$1.2B$1.3B$1.3B$1.3B$1.3B$1.5B
Other, net-$45.9M-$686.0M-$30.7M-$30.2M-$25.1M-$591.0M
Proceeds from (Repayments of) Short-Term Debt—-$1.8B—-$4.1B-$400.0K$1.8B
Payment of Deferred Purchase Consideration-$45.9M-$686.0M-$30.7M-$30.2M-$25.1M-$591.0M
Noncontrolling interest transactions and other-$45.9M-$686.0M-$30.7M-$30.2M-$25.1M-$591.0M
Net cash from financing activities—$1.4B-$1.2B$531.0M-$2.9B-$3.5B
Other financing activities-$45.9M-$686.0M-$30.7M-$30.2M-$25.1M-$591.0M
Noncontrolling Interests Activity and Other-$45.9M-$686.0M-$30.7M-$30.2M-$25.1M-$591.0M
Repurchases of common stock$2.1B$1.2B$692.2M$708.1M$1.5B$2.4B
Net change in short-term borrowings—-$1.8B—-$4.1B-$400.0K$1.8B
Net Change in Short-term Borrowings and Indebtedness to Subsidiaries—-$1.8B—-$4.1B-$400.0K$1.8B

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$977.7M$156.0M$1.4B$6.7B$677.9M$3.0B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$428.8M$132.0M$275.4M$31.7M—$67.0M
Net increase (decrease) in cash—-$175.0M$282.5M$6.4B—-$2.0B